CONCLUSIONS
HER2 POSITIVE GASTRIC CANCER
In brief, pyrotinib alone and combined with docetaxel had shown acceptable safety profile in HER2 positive gastric cancer. Pyrotinib plus docetaxel might not further improve the efficacy.